 |
General
tips
- If you have questions about the condition of the vaccine
at the time of delivery, you should immediately place vaccine
in recommended
storage; and call the Merck Vaccine Customer Center at 1-877-VAX-MERCK (1-877-829-6372), or call
the CDC at 1-800-CDC-INFO (1-800-232-4636).
- Rotate
stock so that the shortest-dated vaccine is used first.*
- Ensure
that the refrigerator is plugged into an outlet in a protected
area where it cannot be disconnected accidentally.*
- Record
refrigerator and freezer temperatures twice a day in a
temperature log.*
- All vaccines must be discarded after the
expiration date; expired or damaged Vaccines for Children
(VFC) vaccines must be returned to your State Immunization
Program.
- For general questions concerning the proper storage and
handling of Merck vaccines, please contact the Merck Vaccine
Customer
Center at
1-800-MERCK-90
(1-800-637-2590),
Monday through Friday,
8:00 am–7:00 pm ET.
- Before administering RotaTeq, please read the Prescribing
Information and Patient
Product Information.
- RotaTeq is indicated for the prevention
of rotavirus gastroenteritis in infants and children
caused by the serotypes G1, G2, G3, and G4 when administered
as a 3-dose series to infants between the ages of 6 to
32 weeks.
- The vaccination series consists of 3 ready-to-use liquid
doses of RotaTeq administered orally starting at 6 to 12 weeks of age,
with the subsequent doses administered at 4- to 10-week intervals. The
third dose should not be given after 32 weeks of age.
Select safety information
- RotaTeq should not be administered
to infants with a demonstrated history of hypersensitivity
to the vaccine or any component
of the vaccine.
- No safety or efficacy data are available
for the administration of RotaTeq to infants who are potentially
immunocompromised
or to infants with a history
of
gastrointestinal disorders.
- Caution is advised when considering whether
to administer RotaTeq to individuals with immunodeficient
contacts.
- In clinical trials, the most common adverse events
included diarrhea, vomiting, irritability, otitis media,
nasopharyngitis, and bronchospasm.
- In post-marketing experience,
intussusception (including death) and Kawasaki disease
have been reported in infants who
have received RotaTeq.
- RotaTeq may not protect all vaccine
recipients against rotavirus.
Before administering RotaTeq, please read the Prescribing
Information
and Patient
Product Information.
*Centers for Disease
Control and Prevention. Vaccine storage and handling
(Appendix C). In: Atkinson W, Hamborsky J, McIntyre L,
Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable
Diseases. 10th ed. Washington, DC: Public Health
Foundation; 2007:C1–C20.
RotaTeq is a registered trademark of Merck & Co.,
Inc.
|
